PCM
LPCN icon

Prelude Capital Management’s Lipocine LPCN Stock Holding History

Prelude Capital Management’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$101K Buy
+12,630
New +$110K 0.01% 1053
2015
Q4 		– Sell
-329
Closed -$66K – 1581
2015
Q3 		$66K Buy
+329
New +$76.1K 0.01% 966
2014
Q4 		– Sell
-4,055
Closed -$421K – 2038
2014
Q3 		$421K Buy
4,055
+478
+13% +$59.4K 0.06% 432
2014
Q2 		$371K Buy
+3,577
New +$428K 0.05% 491

Other funds holding LPCN

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Prelude Capital Management's LPCN Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Lipocine (LPCN) in Q1 2026: 12,630 shares worth $101K. The stake represents 0.01% of the portfolio and ranks #1053 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in LPCN as recently as Q3 2015.

Prelude Capital Management first reported a position in LPCN in Q2 2014 and has held it in 4 quarters since. The position peaked at $421K in Q3 2014. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

  • Prelude Capital Management held 12,630 shares of Lipocine worth $101K as of Q1 2026.
  • Lipocine was a new Prelude Capital Management position in Q1 2026.
  • Lipocine made up 0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1053 holding.
  • Prelude Capital Management first reported a position in Lipocine in Q2 2014 and has held it in 4 quarters since.
  • Prelude Capital Management's Lipocine position peaked at $421K in Q3 2014.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.